Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.

Baheti G, Kiser JJ, Havens PL, Fletcher CV.

Antimicrob Agents Chemother. 2011 Nov;55(11):5294-9. doi: 10.1128/AAC.05317-11. Epub 2011 Sep 6.

2.

Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.

Baheti G, King JR, Acosta EP, Fletcher CV.

AIDS. 2013 Jan 14;27(2):221-5. doi: 10.1097/QAD.0b013e32835a9a2d.

3.

Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.

Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL; Adolescent Trials Network for HIV/AIDS Interventions..

Antimicrob Agents Chemother. 2008 Feb;52(2):631-7. Epub 2007 Nov 19.

4.

Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2).

Hirt D, Ekouévi DK, Pruvost A, Urien S, Arrivé E, Blanche S, Avit D, Amani-Bosse C, Nyati M, Legote S, Ek ML, Say L, McIntyre J, Dabis F, Tréluyer JM.

Antimicrob Agents Chemother. 2011 Jun;55(6):2961-7. doi: 10.1128/AAC.01377-10. Epub 2011 Apr 4.

5.

Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.

Castillo-Mancilla JR, Zheng JH, Rower JE, Meditz A, Gardner EM, Predhomme J, Fernandez C, Langness J, Kiser JJ, Bushman LR, Anderson PL.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90. doi: 10.1089/AID.2012.0089. Epub 2012 Oct 10.

6.

Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.

Burns RN, Hendrix CW, Chaturvedula A.

J Clin Pharmacol. 2015 Jun;55(6):629-38. doi: 10.1002/jcph.461. Epub 2015 Feb 4.

7.

Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.

Jackson A, Moyle G, Watson V, Tjia J, Ammara A, Back D, Mohabeer M, Gazzard B, Boffito M.

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):275-81. doi: 10.1097/QAI.0b013e3182829bd0.

PMID:
23274933
8.

Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.

Hawkins T, Veikley W, Durand-Gasselin L, Babusis D, Reddy YS, Flaherty JF, Ray AS.

Antimicrob Agents Chemother. 2011 Apr;55(4):1549-55. doi: 10.1128/AAC.00910-10. Epub 2011 Jan 31.

9.

Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue.

Louissaint NA, Cao YJ, Skipper PL, Liberman RG, Tannenbaum SR, Nimmagadda S, Anderson JR, Everts S, Bakshi R, Fuchs EJ, Hendrix CW.

AIDS Res Hum Retroviruses. 2013 Nov;29(11):1443-50. doi: 10.1089/AID.2013.0044. Epub 2013 May 29.

10.

Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.

Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R, Grassi J, Clotet B.

Antimicrob Agents Chemother. 2009 May;53(5):1937-43. doi: 10.1128/AAC.01064-08. Epub 2009 Mar 9.

11.

Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?

Adams JL, Sykes C, Menezes P, Prince HM, Patterson KB, Fransen K, Crucitti T, De Baetselier I, Van Damme L, Kashuba AD.

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):260-6. doi: 10.1097/QAI.0b013e3182794723.

12.

Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study.

Chen J, Flexner C, Liberman RG, Skipper PL, Louissaint NA, Tannenbaum SR, Hendrix CW, Fuchs EJ.

J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):593-9. doi: 10.1097/QAI.0b013e3182717c98.

13.

Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.

Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):298-303.

PMID:
18398970
14.

Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.

Benaboud S, Hirt D, Launay O, Pannier E, Firtion G, Rey E, Bouazza N, Foissac F, Chappuy H, Urien S, Tréluyer JM.

Antimicrob Agents Chemother. 2012 Feb;56(2):857-62. doi: 10.1128/AAC.05244-11. Epub 2011 Nov 28.

15.

The pharmacokinetics and viral activity of tenofovir in the male genital tract.

Vourvahis M, Tappouni HL, Patterson KB, Chen YC, Rezk NL, Fiscus SA, Kearney BP, Rooney JF, Hui J, Cohen MS, Kashuba AD.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):329-33. doi: 10.1097/QAI.0b013e3181632cc3.

16.

Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.

Duwal S, Schütte C, von Kleist M.

PLoS One. 2012;7(7):e40382. doi: 10.1371/journal.pone.0040382. Epub 2012 Jul 11. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/fb73d0f4-1cd8-481d-bddd-20439896102a.

17.

A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel.

Schwartz JL, Rountree W, Kashuba AD, Brache V, Creinin MD, Poindexter A, Kearney BP.

PLoS One. 2011;6(10):e25974. doi: 10.1371/journal.pone.0025974. Epub 2011 Oct 19.

18.

Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.

Jullien V, Tréluyer JM, Rey E, Jaffray P, Krivine A, Moachon L, Lillo-Le Louet A, Lescoat A, Dupin N, Salmon D, Pons G, Urien S.

Antimicrob Agents Chemother. 2005 Aug;49(8):3361-6. Erratum in: Antimicrob Agents Chemother. 2008 Feb;52(2):808.

19.

Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.

Goicoechea M, Jain S, Bi L, Kemper C, Daar ES, Diamond C, Ha B, Flaherty J, Sun S, Richman D, Louie S, Haubrich R; California Collaborative Treatment Group..

AIDS. 2010 Mar 13;24(5):707-16. doi: 10.1097/QAD.0b013e32833676eb.

PMID:
20087154
20.

Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.

Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, Cohen MS, Kashuba AD.

Sci Transl Med. 2011 Dec 7;3(112):112re4. doi: 10.1126/scitranslmed.3003174.

Supplemental Content

Support Center